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Objectives To estimate the incidence of severe infection and investigate the associated 
factors and clinical impact in a large Systemic Lupus Erythematosus (SLE) 
retrospective cohort.  
Methods All patients in the Spanish Rheumatology Society Lupus Registry 
(RELESSER) who meet ≥ 4 ACR-97 SLE criteria were retrospectively investigated for 
severe infections. Patients with and without infections were compared in terms of SLE 
severity, damage, comorbidities and demographic characteristics. A multivariable Cox 
regression model was built to calculate hazard ratios (HRs) for the first infection.  
Results A total of 3,658 SLE patients were included: 90% female, median age 32.9 
years (DQ 9.7) and mean follow-up (months) 120.2 (±87.6). A total of 705 (19.3%) 
patients suffered ≥ 1 severe infection. Total severe infections recorded in these patients 
numbered 1,227. The incidence rate was 29.2 (95% CI:27.6 - 30.9) infections per 1,000 
patient years.  Time from first infection to second infection was significantly shorter 
than time from diagnosis to first infection  (p<0.000). Although respiratory infections 
were the most common (35.5%), bloodstream infections were the most frequent cause 
of mortality by infection (42.0%). In the Cox regression analysis, the following were all 
associated with infection: age at diagnosis (HR 1.016; 95% CI:1.009-1.023), Latin-
American (Amerindian-Mestizo) ethnicity (HR 2.151; 95% CI:1.539-3.005), 
corticosteroids (≥10 mg/day) (HR 1.271; 95% CI: 1.034-1.561), immunosuppressors 
(HR 1.348; 95% CI:1.079-1.684), hospitalization by SLE (HR 2.567; 95% CI:1.905-
3.459) , Katz severity index (HR 1.160; 95% CI:1.105-1.217), SLICC/ACR damage 
index (HR 1.069; 95% CI:1.031-1.108) and smoking (HR1.332; 95% CI:1.121-1.583). 
Duration of antimalarial use (months) proved protective (HR 0.998; 95% CI: 0.997-
0.999). 
Conclusions Severe infection constitutes a predictor of poor prognosis in SLE patients, 
is more common in Latin Americans and is associated with age, previous infection and 














1. Introduction  
 
Infection remains an important cause of mortality and morbidity in patients with 
Systemic Lupus Erythematosus (SLE). Severe infection occurred in 11-45% of SLE 
patients depending on case definition, study population, observation period, etc (1-7).  
Although several centres reported their incidence of infection, specific studies on severe 
infection from large multicenter SLE cohorts are lacking.  Roughly 30% of deaths in 
SLE patients are related to infections and recent data from a multicenter French registry 
suggests that overall mortality for infectious diseases in SLE is higher than thought (8). 
Additionally, severe infections account for 11-23% of all hospitalization in SLE patients 
(3, 9,10), with hospitalization rates for serious infections 12 times higher than that in 
patients without SLE (11), thus forming a significant part of the direct health-related 
costs associated with SLE (12).  
Several factors are associated with a predisposition to infection in SLE patients, 
including disease-related factors, immunosuppressant and corticosteroid use and 
intrinsic immune deregulations (13-15). However, the relative contribution of each is 
not well known and comprehensive infection risk factor analysis is lacking. To 
determine the density of  incidence of severe infection, delineate any associated factors 
and explore its clinical impact, we analyzed cumulative infection data from the 
RELESSER-T registry (Spanish Society of Rheumatology Lupus Registry - 
retrospective phase), a very large, non-selected multicenter, well-characterized SLE 
patient cohort containing abundant data on comorbidities (16).  
 
 
2. Methods  
Patients from the RELESSER-T registry who met at least 4 ACR-97 SLE criteria were 
included. The variables, definitions, processes and methodological characteristics of the 
registry have been previously described in detail (17, 18). In short, RELESSER- T is a 
multicenter, hospital-based registry, with retrospective cross-sectional collection of data 
from a large representative sample of adult non-selected patients with SLE attending 
Spanish rheumatology services from the public national health system. The patients 
were consecutively included until deadline of the study. Forty-five centers were 
involved and all of the participating research carried a specific training on the study 
procedures and on the use of SLE assessment tools (i.e., activity, severity and damage 
indexes). A total of 359 variables per patient were collected, with highly standardized 
definitions, encompassing sociodemographic data, cumulative clinical and laboratory 
characteristics as well as comorbidities and Charlson index, all of which were 
retrospectively recorded until the last available visit per RELESSER, including 
deceased. SLICC/ACR/Damage index (SDI), Severity Katz index (SKI) (19) and 
activity (SELENA-SLEDAI) (S-SLEDAI) at the last visit (when enrollment occurred) 
were calculated. Regarding treatments, the use of glucocorticoids (GC) and 
immunosuppresants (IS) was recorded in three ways: “use at last visit”, “any use” and 
“use at the time of the infection”. Only in the case of antimalarials was time of exposure 
(months) also recorded.  
The first patient was enrolled in October 2011 and data collection was completed in 
August 2012.  
Severe infection was defined as either the need for hospitalization with parenteral anti-
biotherapy for a potentially fatal infection or death caused by the infection. Isolation of 
the causative agent was not required in every case, with final classification as an 
infection being made using standard clinical criteria. Nevertheless, just in case of no-
isolation, a strict clinical diagnosis of infection, with a response to antibiotics, was also 
classified as an infectious event. Only infections recorded during the follow-up period 
were included. We considered death due to infection only when it had a decisive 
influence on the death, based on RELESSER investigator criteria.    
2.1 Statistical analysis  
Numerical variables are expressed as mean and standard deviation for those having a 
normal distribution, and as median and interquartile range for non-normal distributions 
(Kolmogorov test). The categorical variables are described by absolute frequency and 
percentage. 
The rate (density) of incidence of infection during periods of patient monitoring was 
calculated, comparing incidence densities based on exposure (assessed retrospectively) 
to various factors including comorbidities etc., and calculating the relative risks for 
each. 
Survival analysis (Kaplan-Meier) was conducted to assess when and how frequently the 
infections occurred as a function of the length of the follow-up period. Subsequent 
comparisons between survival curves were made using a log-rank test. 
Comparisons of numerical variables were performed using a Student t test or a Mann-
Whitney U test, according to normality adjustments, and categorical variables using a 
Chi square (or Fisher’s exact test as necessary). 
To assess the temporal evolution, annual rates were smoothed using moving averages 
(five-year periods) to depict time trends, thereby avoiding short-term variations. 
Variables reaching statistical significance in the bivariate analysis and those considered 
clinically meaningful (e.g., alcohol abuse etc.)  were entered into a multivariate model 
(Cox proportional hazards regression) using the forward LR entering method. Given 
that the dependent variable (severe infection) corresponded to a model of "repeated 
events", a variation of the Cox model (Andersen-Gill), which takes into account the 
given circumstances, was also carried out (20). 
Variables ultimately included in the multivariable models were sex, ethnicity, age at 
diagnosis, previous severe infection, tobacco use, Charlson index, corticoid (any time), 
immunosuppressants (any time), time on antimalarials (months), hospitalization by 
active SLE (excluding by infection), lupus nephritis, last S-SLEDAI, SDI and SKI 
index, chronic hepatopathy, HCV infection, AISD, COPD, diabetes, malignancy, 
splenectomy and alcohol abuse.  
The IBM-SPSS for Windows statistical software package (v. 19.0) was used for all 
statistical analyses. Significance was defined as p < 0.05. 
 
 
2.2 Ethical issues 
 Study procedures complied with the Helsinki Declaration (2008 Seoul update). 
Authorizations were obtained from the corresponding research ethics committee at each 
facility  
3. Results  
A total of 3,658 SLE patients were included, 90% female, median age 32.9 years, 
interquartile range (IQR):19.4. Regarding ethnic distribution, 93% were Caucasian, 5% 
Hispanic (Latin-American: Amerindian or Mestizo) (N=185) and less than 1% other 
ethnic groups. Mean follow-up (months) was 120.2 (SD: ±87.6; range: 508). 
The main clinical characteristic of the cohort has been extensively described elsewhere 
(15). The ACR97 SLE criteria distribution is showed in table 1. The median S-SLEDAI 
score at time of last evaluation was 2.00 (IQR: 4), median SDI was 1 (IQR: 2) and 
median SKI score was 2 (IQR: 2). SLE-related treatments at the time of the 
RELESSER-T assessment (corresponding to the last visit before enrolment), at the time 
of the infection, and cumulative figures are shown in Table 2. GC doses at the infection 
time were: <10 mg/day 53.1%, between 10-30 mg/day, 30.2% and >30mg/day, 16.7%.  
Mean time (months) on antimalarial treatment during the disease course was 78.4 
(±78.4). 
A total of 705 (19.3%) patients suffered ≥ 1 severe infection. The total number of severe 
infections recorded was 1,227. The mean infection rate per patient was: 1.7 (SD±1.25) 
and the median was 1; 426 patients (60.4%) had only one infection, 266 (37.7%) 2 to 5 
infections and 13 (1.9%) ≥ 6. The incidence rate was 29.2 (95% CI: 27.6 - 30.9) 
infections / 1000 patient years.  The incidence rate for a second infection was 71.1 (95% 
CI: 63.1 -79.8) infections/1000 patient years. The time elapsed from first infection to 
second infection was lower than the time from baseline to first infection (median time 
1.86 vs. 5.61 years, log rank p<0.000). (Figure 1),  
The SKI was higher in patients with ≥ 1 severe infection compared to the whole cohort, 
even when excluding patients with GC (>10mg) or IS (whichever) at the time of the 
severe infection (N=244; SKI: 3.41±1.65 vs. 2.65±1.67, p <0.0001). When comparing 
patients with only one infection versus those with ≥ 2, those with > 1 infection had a 
higher SKI score (4.35 ±2.05 vs. 3.42 ±1.86, p=0.000) and a higher SDI score (3.33 
±2.75 vs. 1.84 ±1.98, p=0.000] at the last assessment.  
Regarding etiologic agents, there was a clear predominance of bacterial causes (51.9%), 
with 30.4% corresponding to unknown cause (Table 3). The rate of incidence of 
mycobacterial infections was 1/1000 patient-years. Analysing the soft rates (mobile-
means every 5 years), a steady incidence rate was observed throughout the follow-up 
period. However, when mycobacterial infection rates were analysed, the incidence rate 
showed an annual decrement (p=0.02).  
Concerning localization, the respiratory tract was the most frequently involved (35.5%), 
followed by the urinary tract (15.0%) (Table 3).  A total of 208 (5.7%) patients died 
during follow-up, 24.5% by infection. The predominant localization for the fatal 
infection was the circulatory stream (bacteraemia, regardless of their source) (42.0%), 
followed by respiratory-related ones (34.0%).  
3.1 Bivariate analysis  
Several variables were associated with severe infection in the bivariate analysis, with 
density of incidence serving as a dependent variable (table 4), highlighting the 
hospitalization by SLE (Relative Risk: 5.67) and immunosuppressant use (RR: 10.20). 
Several  co-morbidities/situations  were also associated with severe infection, such as 
occurred with tobacco smoking (any history) (RR: 1.35) (Table 4). Furthermore, in the 
bivariate analysis any history of smoking was also associated with respiratory infections 
(RR: 1.36). 
Regarding antimalarials, current and past use of antimalarials were protective factors 
[RR 0.49 (95% CI: 0.43-0.57) and 0.76 (95% CI: 0.65-0.88), respectively p=0.0000]. 
Furthermore, when quintiles of time on antimalarials (months) were analyzed, we 
observed an inverse relationship with the incidence of severe infection; namely, a 
proportional decrease in the incidence ratio with each quintile, from RR: 1 for Q1 (9.4 
months on antimalarials) to RR: 0,66 (95% CI: 0,53-0,84) for Q5 (68.3 months). 
Specifically, antimalarial users suffered viral infections less frequently than non-users 
(2.8% in users vs. 5.8% in non-users, p<0.001).  
GC use at the time of the infectious event was associated with increased viral (14.6% 
vs. 11.1%) and fungal infections (3.8% vs. 0.8%), with a higher percentage of agent 
isolations (75.8% vs. 62.8% in non-GC users) (p<0.0001). 
We also observed an association between GC at time of infection and mycobacterium as 
an etiologic agent: 3.7% in GC users vs. 0.2% in non-GC users (any dose), p <0.00001. 
As shown in Table 4, there were differences in cumulative IS use between patients with 
and without severe infection. Interestingly, 45.1% of patients that died by infection were 
on IS at that time vs. 9.6% of the surviving patients with severe infection (p<0.001). 
Furthermore, 45.1% of the patients that died by infection were on GC (> 10 mg/day) vs. 
9.5% of survivors (p<0.001). 
In a bivariate sub-analysis of mycobacterial infections, the following factors were all 
associated with this group of microorganism: Hospitalization by SLE (RR = 2.88; 
95%CI:1.33-6.23; p= 0.007), renal disease (RR = 1.98; 95%CI:1.08-3.66; p = 0.04), 
severity [SKI>4: RR = 2.10 (1.10-4.03), p=0.04] and comorbidity [Charlson>4: 
RR=2.47 (95%CI:1.29-4.76), p=0.009].  
 
3.2 Multivariable analysis  
In the Cox proportional-hazards regression model, which used time until first infection 
as the dependent variable, the following were associated with severe infection: age at 
diagnosis, Latin-American ethnicity, any history of glucocorticoid (≥10 mg/day), 
immunosuppressor or tobacco use, time on antimalarials (months), hospitalization due 
to SLE, renal involvement, SKI, and SDI (Table 5). When the IS were considered 
separately, Rituximab (HR=1.61, p<0.001), Abatacept (HR=1.58, p=0.01) and 
Mycophenolate mofetil or Mycophenolic acid (HR=1.41, p=0.01) showed all of them 
statistical significative association with severe infection. 
 
 
When using a time repeated-events Cox regression (Andersen-Gill variant) model, with 
time of follow-up to infection being the dependent variable, results proved similar 
(Table 5), although immunosuppressant use, time on antimalarials and SDI lost 
statistical significance. Worth noting, however, is that previous severe infection reached 
significance only in the last model.  
4. Discussion  
The incidence of severe infection in SLE patients in the RELESSER registry (19.3%) 
was not very different than previous reports involving other large cohorts (4, 9, 21, 22), 
although certainly lower than in previous studies from monocentric cohorts in Spain, 
ranging from 29 to 38% (23, 24), or than was recently reported by Feldman et al in a 
study involving an extensive administrative SLE database from the USA (25) . 
Differences in patient selection and/or time of follow-up could explain these 
discrepancies or, as in the case of the North American cohort, the explanation might lie 
rather in ethnic or heath system differences. In fact, these patients were treated under 
Medicaid, a public health insurance program for low-income individuals, a 
socioeconomic status that could influence the infection risk (25).  
Consistent with most other studies, the RELESSER data confirm that respiratory 
infections are the most common severe infection in SLE (3, 21-28). 
Regarding aetiology, bacteria were the most common agent involved followed by virus 
and fungus, which is also consistent with previous reports (25, 29). The percentage of 
infections of unknown origin was relatively high (a third of the total), but that was not 
unexpected, given the high percentage of respiratory infections in this cohort. In fact, in 
SLE, as in the general population the aetiology of pneumonias remains unknown in 
~50% of all cases (15, 30-32).  
 
There are scarce, reliable data concerning mycobacterium infections in the largest 
cohorts of SLE. The reported prevalence of M. tuberculosis infection in SLE patients 
ranges widely, from 5% to 30% (33, 34). A total of 42 mycobacterium infections (3.5%) 
were registered in RELESSER, equivalent to a prevalence of 1.14% in the global 
RELESSER cohort. This prevalence is higher than the mycobacterium tuberculosis 
infection rate expected in the general Spanish population (34). Furthermore, consistent 
with other studies (33, 35, 36), we found a higher proportion of extrapulmonary 
mycobacterium infections than expected, with an even higher percentage of 
extrapulmonary (vs. pulmonary) in our patients (57.1%). Additionally, we observed that 
this infection tended to appear during the first years of the SLE course and was 
associated with GC use at the time of infection, suggesting a relationship exists between 
higher disease activity and higher levels of immunosuppressive therapy.  
We found an association, previously unreported, between tobacco use and recurrent 
severe infection in the RELESSER database. This is not surprising, since active 
smoking increases the risk of developing community-acquired pneumonia in the general 
population (37, 38). Intriguingly, despite the fact that pneumonia is the most common 
severe infection in SLE, studies specifically addressing pneumonia in SLE have failed 
to demonstrate tobacco use as a specific risk factor (15, 31). This apparent absence of 
association could be explained by its limited statistical power or, alternately, tobacco 
use could be a risk factor for any type of infection, not just respiratory ones. In fact, 
tobacco use increases an individual’s susceptibility to bacterial infections in general, 
compromising the anti-bacterial function of leukocytes, including neutrophils, 
monocytes, T and B cells (39). In any case, we have demonstrated an association 
between tobacco use and respiratory infections in the RELESSER data.  
According to our findings, a previous infectious event appears to increase the risk of a 
new infection in SLE patients, a fact only sporadically explored (40). While this risk 
factor could be a mere consequence of persistent predisposing factors that increase the 
susceptibility to recurrent infections, our data provides information about the global risk 
of infection, shedding light on unknown predisposing factors.  
The association of severe infection with IS or GC use is well known (1-5,13). Any use 
of GC ≥ 10mg increases the risk of infection in our study, and 84% of the patients were 
been treated with GC at the infection time. These findings reinforce the role of GC as 
severe infection risk factor in SLE. Perhaps more interesting from our analysis is that 
the use of these treatments at the time of infection increases the risk of mortality from 
severe infection. On the other hand, a negative association between antimalarials 
exposure time and severe infection was observed in our study, reinforcing the possible 
role these drugs play in protecting against infection, a finding previously reported (25, 
27, 41, 42). Our results, however, do not agree with the other available multicenter 
study, which analyzed the exposure time to antimalarials in the GLADEL cohort.  In 
that multi-nation inception cohort, no association was found between infection 
prevalence or death by infection and antimalarial exposure time.  However, the follow-
up period in this study was relatively short, with low numbers of infection and lesser 
mean durations of antimalarial drug exposure (48.5 months vs. 78.4 in RELESSER) 
(43). An alternative, and somewhat provocative, explanation could lie in ethnic factors, 
given the Latin-American origins of the entire GLADEL cohort. While those 
differences may reflect the low severity of lupus in the European Caucasian population, 
one could also speculate that antimalarials might be less effective in Hispanics. This 
would also explain why we found a higher incidence of severe infection in this ethnic 
minority in our own study. Interestingly, in our analysis, the association of exposure 
duration with antimalarials was independent of severity, as measured by a validated 
quantitative severity index. This suggests the absence of a cofounding variable since it 
points to a less severe cases bias. The alkalinization of phagolysosomes and the 
inhibition of DNA replication has been posited as one mechanism explaining the 
protective ability of antimalarials, particularly against intracellular microorganisms such 
a salmonella, viral agents, etc. (44-48). Consistent with this, protection against viral 
infections was observed in our analysis.  
Finally, the protective effect of the antimalarials on infection risk could be reduced by 
the tobacco use, even though both factors showed an independent effect on infection 
risk in our statistical models. 
We identified age at diagnosis as an independent factor associated with infection in this 
study, even when adjusted for co-morbidity as measured by the Charlson comorbidity 
index. This finding suggests that lupus exerts perhaps more impact over the immune 
system with increasing age than previously realized, an explanation that makes 
biological sense. In fact, in the general population the incidence of pneumonia increases 
with aging (49). 
A higher risk of infection was identified in the Latin-American (Amerindian-Mestizo) 
minority. This ethnic difference has been previously noted in Afro-American SLE 
patients (25, 50) but not, to the best of our knowledge, in Latin Americans. Indeed, 
Feldman et al observed a slightly reduced risk of serious infection among Hispanics 
(HR 0.90 [95% CI 0.82–0.99]) in their previously named analysis. If confirmed, our 
results are particularly interesting, given that the difference was adjusted by severity and 
that the Latin American patients from the RELESSER cohort lived in Spain during the 
observation period and had complete access to the same public and universal health 
system as native Caucasian patients. This suggests that ethnicity, and not simply 
severity or socioeconomic factors, influences the incidence of infection.  
The primary objective of our study was to explore the differences between SLE patients 
with or without previous severe infection. According to our data, SLE patients with 
serious infection suffer more severe disease. Not only are they more frequently 
hospitalized for SLE activity, but they also seem to have lower survival rates than 
patients without such infections. An independent relationship between SLE severity and 
pneumonia has been previously reported (15). This is not an unexpected finding given 
the fact that SLE itself entails several immunologic disorders predisposing individuals 
to infection (1, 14). However, weighing the impact of severity and immunosuppressive 
treatment on severe infection incidence remains problematic due to the presence of 
collinearity, as the most severely affected patients tends to receive more 
immunosuppressive therapy.  
Some limitations of this study must be acknowledged. Several variables, such as 
measures of activity and damage, were not documented at the time of infection due to 
the multi-purpose nature of the RELESSER-T registry, which was never specifically 
designed to study infection in SLE. Although its retrospective design has an inherent 
bias, we believe that a bias towards unreported infections was unlikely given the 
definition of severe infection used in our study, which encompassed hospitalization. 
This definition of severe infection could exclude some patients suffering from 
pneumonia or others severe infections not subject to hospitalization. However, given the 
characteristics of our Sanitary Health System, where the vast majority of patients with 
severe infections are managed inpatient, we believe our cohort sufficiently 
comprehensive and representative of severe infection in SLE. 
Concerning SLE characteristics and covariates, the large number of patients and the 
special standardization effort carried out (17) minimize the impact of the retrospective 
design in missing data and quality.  
The relative rates of mortality by infection in SLE patients are consistent in most 
cohorts, accounting for at least a quarter of all deaths (2, 3, 51-53). Interestingly, blood 
stream infections were the first cause of fatal infection in our cohort, supplanting 
respiratory-related causes at the top of the list. These results reinforce previous findings 
that lupus patients with bacteraemia episodes have poor outcomes (54-56). Strategies to 
reduce bacteraemia-related mortality - such as immediate instauration of antibiotic 
therapy if sepsis is suspected and others (e.g., the so-called “surviving sepsis campaign” 
strategy) should be implemented with particular care in SLE febrile patients, 
particularly patients on IS (57). In fact, delayed or inadequate antibiotic therapy was the 
most significant independent factor for mortality in SLE-infected patients from one 
intensive care unit (58).  
5. Conclusions 
Our results need to be confirmed in prospective studies; specifically, with a more 
exhaustive inclusion of variables related to infection. Nonetheless, several remarkable 
conclusions can be drawn from our data:  
1. Severe infection is associated with severity and damage in SLE patients. There 
are ethnic differences in the prevalence of infection in SLE, with rates appearing 
to be higher in Latin Americans.  
2. Respiratory bacterial infections are the most commonly found severe infection 
in SLE, although bacteraemia are more often fatal.  Indeed, there is an urgent 
need to implement improvements in both the early detection and aggressive 
management of this dangerous complication of SLE. 
3. A previous infectious event increases the risk of a subsequent infection in SLE 
patients. Tobacco use seems to be a risk factor for severe infection in SLE 
patients. In addition, antimalarials exert a time-dependent protective effect. 
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Tables   
 
Table 1: ACR-97 SLE criteria distribution  
SLE criteria  % (N) 
Malar rash 55.2% (1990) 
Discoid rash 20.9% (747) 
Photosensitivity 60.2% (2160) 
Oral ulcers 44.8% (1639) 
Arthritis 78.0% (2814) 
Serositis  23.0% (821) 
Renal disease 33.7% (1187) 
Central nervous system 8.5% (305) 
Hematologic disorders 80.9% (2947), 
Immunologic disorders 91.3% (3135) 
Antinuclear antibodies 99.1% (3617) 




















Table 2: SLE-related treatments 
 At time of 
RELESSER-T 
assessment 





   
 N % N % N % 
Corticosteroids 1918 52.4% 1009 87.2% 3095   84.6% 
Methotrexate    215 5.9% 39 6.6%   577 15.8% 
Leflunomide     47 1.3% 1 0.2%   127 3.5% 
Azathioprine   431 11.8% 196 33.3% 1140 31.2% 
Cyclophosphamide     53   1.4% 130 22.1%   776 21.2% 
Mycophenolate 
mofetil 
 322 1.4% 117 19.9%   522 14.3% 
Mycophenolic acid   64 1.7% 16 2.7%    85     2.3% 
Antimalarials  2021   55.2% NR NR 2882 78.7% 













Table 3: Localization  and cause of severe infection  
Localization  N % 
Respiratory 425 35.5% 
Urinary tract 180 15.0% 
Soft tissues 159 13.3% 
Bacteraemia /sepsis 141 11.8% 
Gastrointestinal 108 9.0% 
Septic arthritis 39 3.3% 
CNS 33 2.8% 
Endocarditis 11 0.9% 
Others 102 8.5% 
Total 1198 100% 
Agent  N % 
Bacteria 622 51.9% 
Mycobacterium 42 3.5% 
Fungus 27 2.3% 
Virus 143 11.9% 
Unknown  364 30.4% 
























Table 4 Rate of infection in presence or absence of factor and relative risks. Bivariate analysis (dependent 
variable: Density of incidence = number of infections/1000 patients-year) 
Independent 
variables 






RR (95%CI) P value 




30.6 27.6 1.12 (1.03-
1.22) 
0.01 





185 (5.1) 48.5 28.5 1.69 (1.31-
2.16) 
< 0.0001 














45.4 18.3 2.48 (2.21-
2.79) 
0.0001 









38 (1.0) 129.5 28.4 4.56 (3.47-
5.99) 
< 0.0001 
HIV/AIDS 9 (0.2) 102.6 29.0 3.54 (1.82-
6.20) 
0.007 
Hepatitis C virus 
infection 
48 (1.3) 79.0 28.3 2.79 (2.16-
3.61) 
< 0.0001 
Malignancy 207 (5.7) 40.5 28.3 1.40 (1.17-
1.68) 
0.0004 
COPD  98 (2.7) 65.6 28.0 2.34 (1.89-
2.89) 
<0.0001 
Splenectomy 52 (1.4) 53.7 28.8 1.86 (1.33-
2.61) 
0.0004 
Dialysis 106 (2.9) 88.3 27.3 3.31 (2.80-
3.92) 
< 0.0001 











by SLE  
1954 
(53.8) 










IS (any use) 394 
(10.8) 
132.3 13.0 10.20 (9.10-
11.44) 
< 0.0001 
RR = relative risk; SLEDAI = Systemic Lupus Erythematosus Disease Activity Index; SKI= Severity 
Katz index; HIV: Human Immunodeficiency Virus; COPD = Chronic obstructive pulmonary disease; 













Table 5 Cox proportional-hazards regression model. Dependent variable: time to first infection 
 β p value  HR* 95%CI 
Age at diagnosis 0.01566111 0.0000 1.016 1.0091.023 
Hispanic ethnicity 0.76575765 0.0000 2.151 1.5393.005 
Corticoids (≥10 mg/day), any use 0.23954448 0.0224 1.271 1.0341.561 
Time on antimalarials (months)  0.00175786 0.0022 0.998 0.9970.999 
Immunosuppressors, any use 0.29879736 0.0085 1.348 1.0791.684 
Hospitalization by SLE 0.94264204 0.0000 2.567 1.9053.459 
Renal involvement 0.31466771 0.0013 1.370 1.1301.660 
SKI 0.14835582 0.0000 1.160 1.1051.217 
SDI 0.06663931 0.0003 1.069 1.0311.108 




Table 6 Time repeated-events Cox regression. Dependent variable: Time to severe infection  
 β  HR
*
 95%CI p value 
Age at diagnosis (quintiles) 0,1163  1.12 1.07–1.18 0.001 
Male sex 0.3962  1.49 1.22–1.81 0.0001 
Hispanic ethnicity 0.427  2.40 2.29–2.50 0.001 
Corticoids (≥10mg/day), any use 0.2878  1.33 1.15–1.55 0.001 
Hospitalization by SLE 1.0049  2.73 2.22–3.35 0.0000 
SKI 0.062  1.06 1.03–1.10 0.002 
Previous infection (order) 0.8739  2.40 2.29–2.50 0.0000 
*
HR: hazard ratio. SLE= Systemic Lupus Erythematosus; SKI= Severity Katz Index. Enter method: 
Forward likelihood-ratio. Variables not included in the model: Charlson (p =0.134), SLEDAI (p =0.103), 
SLE Damage Index (p= 197), diabetes (p =0.151), malignancy (p =0.145), hepatitis C virus infection (p 

















Figure 1: Comparative survival analysis / infection-free time graphic.  
The time until second infection was lower than time until first infection 
 
 
HR (95%CI):1.82 (1.59- 2.11) 
 
p<0.001 
